189 related articles for article (PubMed ID: 9286756)
1. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
3. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
4. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
[TBL] [Abstract][Full Text] [Related]
5. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
6. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
7. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
Cloos PA; Fledelius C
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504
[TBL] [Abstract][Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
10. Biochemical markers of bone turnover in Paget's disease of bone.
Delmas PD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
[TBL] [Abstract][Full Text] [Related]
11. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
12. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
13. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
14. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation.
Brady JD; Ju J; Robins SP
Clin Sci (Lond); 1999 Feb; 96(2):209-15. PubMed ID: 9918902
[TBL] [Abstract][Full Text] [Related]
15. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
16. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
17. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
Rousseau JC; Chevrel G; Schott AM; Garnero P
Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation.
Krane SM; Kantrowitz FG; Byrne M; Pinnell SR; Singer FR
J Clin Invest; 1977 May; 59(5):819-27. PubMed ID: 404321
[TBL] [Abstract][Full Text] [Related]
19. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover.
Gineyts E; Cloos PA; Borel O; Grimaud L; Delmas PD; Garnero P
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):481-5. PubMed ID: 10642505
[TBL] [Abstract][Full Text] [Related]
20. Cross-sectional evaluation of bone metabolism in men.
Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD
J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
